Discovery of PF-05212384/PKI-587: A phase 2 clinical PI3K/mTOR inhibitor

被引：0
|
作者：
Dehnhardt, Christoph M. [1 ]
Venkatesan, Aranapkam M. [1 ]
Delos Santos, Efren [1 ]
Kaloustian, Semiramis Ayral [1 ]
Broojimans, Natasja [1 ]
Hollander, Irwin [2 ]
Chen, Zecheng [1 ]
Lucas, Judy [1 ]
Mallon, Robert [2 ]
Verheijen, Jeroen [1 ]
Zask, Arie [1 ]
Khafizofa, Gulnaz [1 ]
Bursavich, Matt [2 ]
Richard, David [1 ]
Mansour, Tarek [1 ]
机构：
[1] Pfizer, Pearl River, NY 10965 USA
[2] Wyeth, Pearl River, NY 10965 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2014年 / 248卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
287-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A Phase I study of the dual, intravenous (IV) phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 in combination with irinotecan in patients (pts) with colorectal cancer (CRC) and other advanced solid tumors
    Wainberg, Z.
    Tabernero, J.
    Maqueda, M. A.
    Leong, S.
    Del Conte, G.
    Britten, C.
    Brega, N.
    Davis, C.
    Houk, B.
    Pierce, K.
    Vermette, J.
    Siu, L.
    Brana, I.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 171 - 171
  • [32] The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL) (vol 392, pg 9, 2017)
    Gazi, Mohiuddin
    Moharram, Sausan A.
    Marhall, Alissa
    Kazi, Julhash U.
    CANCER LETTERS, 2019, 461 : 155 - 155
  • [33] A Multi-arm Phase 1 Dose Escalation Study of Safety, Pharmacokinetics, and Pharmacodynamics of the Dual PI3K/mTOR Inhibitors PF-04691502 (oral) and PF-05212384 (IV) in Combination with the MEK Inhibitor PD-0325901 or Irinotecan in Patients with Advanced Cancer
    Britten, C.
    Wainberg, Z.
    Tabernero, J.
    Alsina Maqueda, M.
    Leong, S.
    Sessa, C.
    Millham, R.
    Gallo, J.
    Siu, L.
    Brana, I.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 109 - 109
  • [34] Phase I dose-escalation study of the dual PI3K/mTORC1/2 inhibitor Gedatolisib (PF-05212384) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumours
    Colombo, I.
    Genta, S.
    Martorana, F.
    Guidi, M.
    Samartzis, E. S. P.
    Brandt, S.
    Gaggetta, S.
    Moser, L.
    Pascale, M. R.
    Terrot, T.
    Sessa, C.
    Stathis, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S487 - S487
  • [35] Synthesis of PF-04691502, a highly potent PI3K/mTOR dual inhibitor
    Hoffman, Jacqui
    Bailey, Simon
    Cheng, Hengmiao
    Kania, Robert
    Jai, Lei
    Nambu, Mitch
    Ninkovich, Sacha
    Pairish, Mason
    Srirangam, Jay
    Wang, Xiaolong
    Le, Phuong
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [36] Discovery of GDC-0084: A BBB penetrating PI3K/mTOR inhibitor
    Heffron, Timothy
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
  • [37] Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR
    Heffron, Timothy P.
    Ndubaku, Chudi O.
    Salphati, Laurent
    Alicke, Bruno
    Cheong, Jonathan
    Drobnick, Joy
    Edgar, Kyle
    Gould, Stephen E.
    Lee, Leslie B.
    Lesnick, John D.
    Lewis, Cristina
    Nonomiya, Jim
    Pang, Jodie
    Plise, Emile G.
    Sideris, Steve
    Wallin, Jeffrey
    Wang, Lan
    Zhang, Xiaolin
    Olivero, Alan G.
    ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (04): : 351 - 356
  • [38] Biomarker evaluation in phase I clinical trials of selective PI3K and PI3k/mTOR inhibitors
    Spoerke, Jill
    Desai, Rupal
    Patel, Rajesh
    Fredrickson, Jill
    Wang, Yulei
    Levy, Gallia
    Gendreau, Steve
    Lauchle, Jennifer
    Derynck, Mika
    Raja, Rajiv
    Koeppen, Hartmut
    Hampton, Garret
    Yan, Yibing
    Lackner, Mark R.
    CANCER RESEARCH, 2013, 73 (08)
  • [39] Biomarker evaluation In phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors
    Spoerke, Jill
    O'Brien, Carol
    Wu, Jenny
    Desai, Rupal
    Patel, Rajesh
    Raja, Rajiv
    Koeppen, Hartmut
    Amler, Lukas
    Hampton, Garret
    Yan, Yibing
    Lackner, Mark R.
    CANCER RESEARCH, 2012, 72
  • [40] Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design
    Cheng, Hengmiao
    Bagrodia, Shubha
    Bailey, Simon
    Edwards, Martin
    Hoffman, Jacqui
    Hu, Qiyue
    Kania, Robert
    Knighton, Daniel R.
    Marx, Matthew A.
    Ninkovic, Sacha
    Sun, Shaoxian
    Zhang, Eric
    MEDCHEMCOMM, 2010, 1 (02) : 139 - 144
12345